HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt^®)  

作　　者：M. C. O. Ezeibe B. L. Salako F. I. O. Onyeachonam A. David O. O. Aina E. Herbertson M. E. Sanda I. J. Ogbonna E. Kalu N. U. Njoku M. I. Udobi C. A. Akpan M. C. O. Ezeibe;B. L. Salako;F. I. O. Onyeachonam;A. David;O. O. Aina;E. Herbertson;M. E. Sanda;I. J. Ogbonna;E. Kalu;N. U. Njoku;M. I. Udobi;C. A. Akpan(College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria;Nigerian Institute of Medical Research, Lagos, Nigeria)

机构地区：[1]College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria [2]Nigerian Institute of Medical Research, Lagos, Nigeria

出　　处：《World Journal of AIDS》2020年第2期141-148,共8页艾滋病（英文）

摘　　要：In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt<span style="white-space:nowrap;">^&#174;</span>), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt<span style="white-space:nowrap;">^&#174;</span>-treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month;23.98% in the third month;31.76% in the fourth month and 64.12% after the fifth month.In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt<span style="white-space:nowrap;">^&#174;</span>), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt<span style="white-space:nowrap;">^&#174;</span>-treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month;23.98% in the third month;31.76% in the fourth month and 64.12% after the fifth month.

关 键 词：Antivirt^® Opposite Charges’ Electrostatic Attraction Continuous Depletion Of HIV-Infection Loads 

分 类 号：R51[医药卫生—内科学]